EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Deconstructing Exceptional Responses to Immune Checkpoint Inhibition in Recurrent or Metastatic Head and Neck Carcinoma: A Site-Specific Clinical–Biological Synthesis

Giovanni Motta iD, Piero Giuseppe Meliante iD, Pasquale Capasso, Francesco Chiari iD, Giuseppe Tortoriello

Cancers · 27.08.2026 · 18 (17) · 2790

DOI: 10.3390/cancers18172790 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.08.2026. Verfasst von Giovanni Motta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Otolaryngology Head and Neck Surgery Unit, Azienda Ospedaliera di Rilievo Nazionale dei Colli, Ospedale Monaldi, 80131 Naples, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is an aggressive malignancy with a historically poor prognosis. Although immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have established a new first-line standard of care, durable clinical benefit is restricted to a minority of patients, while primary or acquired resistance remains a major clinical challenge. This narrative review aims to provide a conceptual clinical–biological synthesis of immunotherapy in R/M HNSCC through an anatomical and biomarker-driven lens, with a focus on characterizing potential shared features of “exceptional responders”.

Methods

A targeted narrative literature search was conducted across PubMed/MEDLINE and to identify key clinical trials and representative clinical reports of exceptional response to ICIs in R/M HNSCC. The literature was not systematically synthesized to construct a conceptual clinical–biological framework of response and resistance.

Results

Landmark clinical data confirm durable survival benefits with frontline pembrolizumab-based regimens in selected PDL-1 positive populations compared to historical chemotherapy. Qualitative appraisal of illustrative cases and translational cohorts suggests a potential biological hypothesis: exceptional responders, defined as patients achieving unexpected, multi-year complete radiological, pathological, or metabolic remissions, often align with a favorable confluence of a pre-existing “hot” or inflamed tumor microenvironment, preserved antigen presentation machinery, and elevated antigenic novelty driven by viral oncoproteins (HPV, EBV) or high mutational/indel burdens. Conversely, primary and acquired resistance are conceptually associated with defects in antigen processing, immunosuppressive cellular barriers, and alternative immune checkpoints.

Conclusions

Immunotherapy has fundamentally transformed R/M HNSCC management, yet exceptional single-agent responses remain rare. Rather than a definitive or proven biological biomarker, the proposed blueprint represents an integrative hypothesis highlighting the complex interplay of baseline immune inflammation, genomic features, and viral drivers. Translating these observations into broader clinical benefit will require validated biomarker-driven personalization and rationally designed combination regimens.

Schlagwörter

Stichwörter der Autor:innen

Epstein-Barr virus (EBV)exceptional respondershead and neck squamous cell carcinoma (HNSCC)human papillomavirus (HPV)immune checkpoint inhibitorsnarrative reviewnivolumabpembrolizumabstomal recurrencetumor microenvironment

Autor:innen und Institutionen

  • Otolaryngology Head and Neck Surgery Unit, Azienda Ospedaliera di Rilievo Nazionale dei Colli, Ospedale Monaldi, 80131 Naples, Italy.
  • Otolaryngology, Head and Neck Unit, "Santo Spirito" Hospital, 65124 Pescara, Italy.

ORCID-Profile: Giovanni Motta, Piero Giuseppe Meliante, Francesco Chiari

Zitieren

APA

Motta, G., Meliante, P. G., Capasso, P., Chiari, F., & Tortoriello, G. (2026). Deconstructing Exceptional Responses to Immune Checkpoint Inhibition in Recurrent or Metastatic Head and Neck Carcinoma: A Site-Specific Clinical–Biological Synthesis. Cancers, 18(17), 2790. https://doi.org/10.3390/cancers18172790

Vancouver

Motta G, Meliante PG, Capasso P, Chiari F, Tortoriello G. Deconstructing Exceptional Responses to Immune Checkpoint Inhibition in Recurrent or Metastatic Head and Neck Carcinoma: A Site-Specific Clinical–Biological Synthesis. Cancers. 2026;18(17):2790. doi:10.3390/cancers18172790

BibTeX
@article{Motta2026,
  author = {Motta, Giovanni and Meliante, Piero Giuseppe and Capasso, Pasquale and Chiari, Francesco and Tortoriello, Giuseppe},
  title = {Deconstructing Exceptional Responses to Immune Checkpoint Inhibition in Recurrent or Metastatic Head and Neck Carcinoma: A Site-Specific Clinical–Biological Synthesis},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {17},
  pages = {2790},
  doi = {10.3390/cancers18172790}
}
Kostenlos starten →